Details for Patent: 8,193,229
Summary for Patent: 8,193,229
| Title: | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
| Abstract: | Disclosed are methods of treating a hyperproliferative disorder or a disease related to vasculogenesis or angiogenesis in a mammal, comprising administering to said mammal an effective amount of a compound of the formula or a pharmaceutically accepted salt thereof, wherein A, R1, R2, R7, R8, and R9 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. |
| Inventor(s): | Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley |
| Assignee: | AstraZeneca AB , Array Biopharma Inc |
| Application Number: | US12/824,521 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,193,229
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,193,229
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1482932 | ⤷ Start Trial | PA2019007 | Lithuania | ⤷ Start Trial |
| European Patent Office | 1482932 | ⤷ Start Trial | LUC00100 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 1482932 | ⤷ Start Trial | 300974 | Netherlands | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
